X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2600) 2600
male (1561) 1561
female (1521) 1521
antineoplastic combined chemotherapy protocols - therapeutic use (1295) 1295
middle aged (1291) 1291
uracil - administration & dosage (1181) 1181
aged (1152) 1152
tegafur - administration & dosage (1032) 1032
uracil - therapeutic use (1015) 1015
adult (874) 874
uracil - analogs & derivatives (860) 860
oncology (829) 829
animals (736) 736
chemotherapy (485) 485
uracil (480) 480
administration, oral (465) 465
drug combinations (457) 457
treatment outcome (441) 441
cancer (439) 439
tegafur - therapeutic use (420) 420
5-fluorouracil (408) 408
fluorouracil - administration & dosage (404) 404
drug administration schedule (377) 377
mice (375) 375
pharmacology & pharmacy (360) 360
aged, 80 and over (324) 324
leucovorin - administration & dosage (314) 314
fluorouracil (303) 303
antineoplastic combined chemotherapy protocols - administration & dosage (302) 302
antineoplastic combined chemotherapy protocols - adverse effects (301) 301
colorectal neoplasms - drug therapy (301) 301
uracil - adverse effects (301) 301
combined modality therapy (292) 292
chemotherapy, adjuvant (281) 281
cisplatin - administration & dosage (268) 268
adenocarcinoma - drug therapy (261) 261
survival rate (253) 253
uft (244) 244
drug therapy, combination (238) 238
fluorouracil - therapeutic use (237) 237
neoplasm staging (232) 232
stomach neoplasms - drug therapy (230) 230
therapy (224) 224
antineoplastic agents - therapeutic use (221) 221
uracil - pharmacology (218) 218
care and treatment (210) 210
colorectal cancer (209) 209
carcinoma (196) 196
radiotherapy (196) 196
surgery (192) 192
rats (190) 190
patients (187) 187
lung neoplasms - drug therapy (181) 181
antimetabolites, antineoplastic - therapeutic use (180) 180
research (179) 179
pyrimidines (178) 178
uracils (177) 177
leucovorin (174) 174
prognosis (174) 174
liver neoplasms - drug therapy (173) 173
tegafur - adverse effects (173) 173
time factors (166) 166
analysis (162) 162
colorectal neoplasms - pathology (162) 162
toxicity (162) 162
liver neoplasms - secondary (153) 153
hematology, oncology and palliative medicine (152) 152
radiology and nuclear medicine (152) 152
retrospective studies (152) 152
capecitabine (148) 148
disease-free survival (148) 148
medicine & public health (146) 146
diabetes mellitus, type 2 - drug therapy (145) 145
colonic neoplasms - drug therapy (143) 143
piperidines - therapeutic use (143) 143
radiology, nuclear medicine & medical imaging (143) 143
trial (141) 141
medicine (140) 140
prospective studies (135) 135
deoxycytidine - analogs & derivatives (132) 132
radiology (132) 132
tegafur (132) 132
stomach neoplasms - pathology (128) 128
survival analysis (127) 127
dose-response relationship, drug (124) 124
remission induction (123) 123
breast neoplasms - drug therapy (118) 118
clinical trials as topic (118) 118
lymphatic metastasis (118) 118
cisplatin (117) 117
follow-up studies (117) 117
antiviral agents - therapeutic use (116) 116
enzymes (116) 116
antimetabolites, antineoplastic - administration & dosage (115) 115
adolescent (114) 114
dipeptidyl-peptidase iv inhibitors - therapeutic use (114) 114
health aspects (114) 114
adjuvant chemotherapy (113) 113
uracil - pharmacokinetics (113) 113
hypoglycemic agents - therapeutic use (112) 112
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2557) 2557
Japanese (665) 665
Russian (253) 253
Italian (29) 29
German (28) 28
French (21) 21
Ukrainian (11) 11
Chinese (9) 9
Czech (7) 7
Spanish (5) 5
Polish (3) 3
Norwegian (2) 2
Bulgarian (1) 1
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes & metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
BMC gastroenterology, ISSN 1471-230X, 08/2015, Volume 15, Issue 1, p. 98
Background: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with... 
Chronic hepatitis C | Olysio | Viekira Pak | Harvoni | Markov model | Cost-effectiveness | Sofosbuvir | DIAGNOSIS | INTERFERON-ALPHA-2B | VIRUS | MANAGEMENT | RIBAVIRIN | COMPENSATED CIRRHOSIS | HEPATOCELLULAR-CARCINOMA | THERAPY | DISEASE | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Interferons - economics | Markov Chains | Fluorenes - economics | Ribavirin - economics | Humans | Middle Aged | Simeprevir - economics | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Ritonavir - economics | Male | Interferons - therapeutic use | Uridine Monophosphate - economics | Benzimidazoles - economics | Polyethylene Glycols - therapeutic use | Simeprevir - therapeutic use | Sofosbuvir - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Quality-Adjusted Life Years | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Drug Therapy, Combination - economics | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Drug Combinations | Uracil - analogs & derivatives | Economic aspects | Markov processes | Hepatitis C virus | Analysis
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Liver international, ISSN 1478-3223, 2016, Volume 36, Issue S1, pp. 47 - 57
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 07/2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
interferon-free | ledipasvir | sofosbuvir | MK-8742 | ombitasvir | MK-5172 | ABT-450 | asunaprevir | dasabuvir | daclatasvir | Daclatasvir | Ombitasvir | Interferon-free | Ledipasvir | Asunaprevir | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | HCV INFECTION | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2017, Volume 57, pp. 58 - 68
Abstract Background New highly efficacious direct-acting antiviral (DAA) therapies are available to treat chronic hepatitis C viral (HCV) infection.... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Hepatitis | Direct acting antiviral (DAA) | Patient-reported outcomes | Patient-centered outcomes research (PCOR) | Liver | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | REPORTED OUTCOMES | VIRUS-INFECTION | HCV GENOTYPE 1 | SYMPTOM PREVALENCE | NATIONAL-HEALTH | INFORMATION-SYSTEM PROMIS | PSYCHOMETRIC EVALUATION | ROBUST ESTIMATION | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | Quinoxalines - adverse effects | Prospective Studies | Humans | Patient Participation | Fluorenes - therapeutic use | Male | Ritonavir - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Patient-Centered Care - methods | Ritonavir - therapeutic use | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Uracil - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Sulfonamides - adverse effects | Carbamates - adverse effects | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Medicine, Experimental | Medical research | Antiviral agents | Hepatitis C | Drug therapy | Hepatitis C virus | Analysis | patient-reported outcomes | patient-centered outcomes research (PCOR) | hepatitis | direct acting antiviral (DAA)
Journal Article
Journal Article
Value in health, ISSN 1098-3015, 2016, Volume 19, Issue 4, pp. 326 - 334
Abstract Background Interferon-free hepatitis C treatment regimens are effective but very costly. The cost-effectiveness, budget, and public health impacts of... 
Internal Medicine | interferon-free | cost-effectiveness | Medicare | Medicaid | hepatitis C | UNITED-STATES | VIRUS-INFECTION | ANTIVIRAL THERAPY | INTERFERON-FREE REGIMENS | COMPENSATED CIRRHOSIS | ALL-CAUSE MORTALITY | TREATMENT-NAIVE | HEALTH CARE SCIENCES & SERVICES | GENOTYPE 1 INFECTION | HEALTH POLICY & SERVICES | ECONOMICS | ADVANCED LIVER-DISEASE | Anilides - therapeutic use | Markov Chains | Medicaid - economics | Hepatitis C - drug therapy | Fluorenes - economics | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C - economics | Ritonavir - economics | Male | Uridine Monophosphate - economics | Benzimidazoles - economics | HIV Protease Inhibitors - economics | Health Services Accessibility - economics | Ritonavir - therapeutic use | Female | Macrocyclic Compounds - economics | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Severity of Illness Index | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Carbamates - economics | HIV Protease Inhibitors - therapeutic use | Macrocyclic Compounds - therapeutic use | Anilides - economics | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Uracil - economics | Antiviral Agents - economics | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Hepatitis C
Journal Article